February 13, 2015

 

Local teacher says a CT scan caught his cancer and saved his life
ABC Action News – Feb. 11
“I’d seen an article in the paper that Moffitt had gotten a federal grant to do these CT scans,” Devine recalled. David paid $150 to have the CT scan done -- because his insurance didn’t cover the screening, at the time. 

Pregnancy-related risks impact childbearing decisions for meningioma survivors
Oncology Nurse Advisor – Feb. 11
Researchers from Moffitt Cancer Center in Tampa, Florida, developed a survey to identify the impact of a meningioma diagnosis on women’s views about reproductive choices. In a preliminary study, the researchers surveyed women who had received a diagnosis of meningioma to ascertain their personal attitudes toward childbearing and what influences, such as physician recommendations, may have played a role in these attitudes. 

SHOP TALK
Oncology Times – Feb. 10
Lodovico Balducci, MD, Senior Adult Oncology Program leader at Moffitt Cancer Center, has received the fifth annual Enzo Piccinini Prize from the Enzo Piccinini Foundation in partnership with the University of Modena and Reggio Emilia School of Medicine in Italy. 

Tanglewood residents Golf Fore A Cure
Highlands Today – Feb. 10
140 golfers took part in the 10th and final “Golf Fore A Cure” tournament held on the Turtle Run course at the Sun ‘n Lake Golf Club on Sunday. The money raised will go for breast cancer research at the Moffitt Cancer Center in Tampa.  

Moffitt Cancer Center Reports on Faculty Participants in International Discovery of Genetic Risk Factors for Ovarian Cancer
The ASCO Post – Feb. 10
Researchers from Moffitt Cancer Center in Tampa, Florida have participated in a global effort that has identified six new regions of the genome that increase risk of epithelial ovarian cancer, according to a news release from Moffitt. The collaborative study was published recently in Nature Genetics. The study is unique in that it includes a combined analysis of two groups of women who had their genetic profiles completed as part of a large international collaboration. 

Therapy offers hope for advanced melanoma
Dermatology Times – Feb. 9
Nivolumab , a newly developed checkpoint protein inhibitory antibody directed against programmed death-1, or PD-1, with significant clinical activity against melanoma, can treat other malignancies outside of melanoma and renal cell carcinoma, which is one of the big advances with the treatment, according to Jeffrey Weber M.D., Ph.D., senior member of the H. Lee Moffitt Cancer Center, and director, Donald A. Adam Comprehensive Melanoma Research Center in Tampa Bay, Fla. 

Researchers Find Loss of an Important Tumor Suppressor Is Associated With Poor Prognosis in Lung Cancer
Lung Cancer News Today – Feb. 9
Investigators from the Moffitt Cancer Center have made an important discovery that has the potential to significantly impact the future science of oncogenesis. Their findings, which were published in the Dec. 26 issue of PLoS One, show that that breast and lung cancer patients who have low levels of a tumor suppressing protein called tristetraprolin (TTP) have more aggressive tumors and a poorer prognosis than those with high levels of the protein.

Vincristine in Acute Lymphoblastic Leukemia
OncLive – Feb. 8
Jeffrey Lancet, MD,Professor of Oncologic Science and Section Chief for Leukemia, H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida 

Foundation presents merit awards for research into gastrointestinal, genitourinary cancers
HemOnc Today – Feb. 8
The 22 recipients of merit awards in gastrointestinal cancers are:  Andrea M. Abbott, MD, MS, Moffitt Cancer Center; Kamran Ahmed, MD, Moffitt Cancer Center; Benjamin T. Cooper, MD, New York University School of Medicine; Chiara Cremolini, MD, Azienda Ospedaliero-Universitaria Pisana Istituto Toscano Tumori; Gary B. Deutsch, MD, MPH, John Wayne Cancer Institute; Thomas J. Ettrich, MD, Ulm University Hospital; Daniel A. Goldstein, MD, Winship Cancer Institute; Jin He, MD, PhD, Johns Hopkins University School of Medicine; Kavya Krishna, MD, The Ohio State University Comprehensive Cancer Center; Oxana V. Makarova-Rusher, MD, National Cancer Institute; Sheraz Markar, MBBChir, MA, MRCS, MSc, Imperial College; Eric A. Mellon, MD, PhD, Moffitt Cancer Center; Raphael B. Moreira, MD, Centro Oncologico Antônio Ermírio de Moraes; Adnan M. Nagrial, MBBS, Royal Prince Alfred; Lauren M. Postlewait, MD, Winship Cancer Institute; Omar M. Rashid, MD, JD, Moffitt Cancer Center; Jamie C. Riches, DO, Mount Sinai St Luke's; Aaron J. Scott, MD, University of Colorado Denver; Smit Singla, MD, MSc, Roswell Park Cancer Institute; Jesse Joshua Smith, MD, PhD, Memorial Sloan Kettering Cancer Center; Elizabeth Smyth, MB  BAO BCh, MSc, Royal Marsden Hospital; and I-Chen Wu, MD, PhD, Kaohsiung Medical University Hospital.

In Puerto Rico, Health Overhaul Gets An Incomplete
NPR “Shots” blog (Health News from NPR) – Feb. 7
A few months later, he had the procedure performed at the Moffitt Cancer Center in Tampa, Florida. He took his two young kids, ages two and six, to Disney World to celebrate. Now he’s back in San Juan selling cars, and continuing his chemotherapy. He says he feels great. 

Moffitt takes top spot on statewide Cancer Centers List
Tampa Bay Business Journal – Feb. 6
Moffitt Cancer Center took over the top spot on the List with 6,516 analytic cases. Moffitt also had the most non-analytic cases, with 4,511 for a total of 11,027 cases. 

Column: U.S. risks falling behind in medical research (w/video)
Tampa Bay Times – Feb. 6
At its infancy 20 years ago, H. Lee Moffitt Cancer Center & Research Institute in Tampa had only one research scientist overseeing a small lab. Today, more than 800 Moffitt scientists research ways to prevent and treat cancer in one of the most advanced National Cancer Institute Comprehensive Cancer Centers in the country. 

Dabrafenib/Trametinib Combo Continues to Show Benefit
OncLive – Feb. 6
In an interview with OncLive, Jeffrey S. Weber, MD, PhD, a senior member at Moffitt Cancer Center, said that dabrafenib plus trametinib has proven to be efficacious but that other oncologists doubt the curative potential of a BRAF/MEK combination and treat with immunotherapy first.

Candidates get rid of excess campaign cash in many ways
News-Press.com – Feb. 6
The group of about 30 starts in Tampa on Feb. 14, ending in Tallahassee where they’ll meet with legislators to promote state funding for the Moffitt Cancer Center. They’re also soliciting individual donations from friends and associates. Aubuchon lost both parents to cancer, so the cause is important to him.

Patient Voices Essential, as Docs Underreport Toxicities
Medscape – Feb. 5
“This study documents the gap between patient-reported and clinician-reported adverse reactions,” said Andy Trotti, MD, from the Moffitt Cancer Center in Tampa, Florida. “It is not surprising that there are differences,” he told Medscape Medical News. “The next step is converting patient-reporting of the most relevant events that are study-specific directly into common terminology criteria as a routine practice in clinical trials.”

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.